68 IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
Giorgio Rivella(University of Padua), Marco Scarpa(University of Padua), Roberta Salmaso, Giulia Noaro(AULSS 2 Marca Trevigiana), Monica Ortenzi(Marche Polytechnic University), Giulia Becherucci(University of Padua), Laura Gavagna(AULSS 2 Marca Trevigiana), Salvatore Pucciarelli(Azienda Ospedale - Università Padova), Ignazio Castagliuolo(University of Padua), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Ivana Cataldo(Ospedale SS. Annunziata), Giuseppe Portale(University of Southern California), Giulia Pozza(University of Padua), Melania Scarpa(University of Padua), Daunia Verdi(ASL Roma), Francesca Bergamo(Istituto Oncologico Veneto), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Marco Massani(AULSS 2 Marca Trevigiana), Silvia Negro(University of Padua), Stefano Brignola(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Antonio Scapinello(Istituto Oncologico Veneto), Matteo Fassan(University of Padua), Pierluigi Pilati(Istituto Oncologico Veneto), Francesco Cavallin, Marco Agostini(University of Padua), Licia Laurino(University of Padua), Gianluca Businello(University of Padua), Luca Saadeh(University of Padua), Gaya Spolverato(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Carlotta Ceccon(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Isabella Mondi(Ospedale di Mirano), Giovanni Pirozzolo(Ottawa Hospital), Barbara Di Camillo(University of Padua), Alessandra Piccioli, Alfonso Recordare(Ca' Foncello Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Chiara Vignotto(University of Padua), Gaia Tussardi(Azienda Ospedale - Università Padova), Anna Pozza(University of Padua), Corrado Da Lio(Ospedale di Mirano), Andrea Porzionato(University of Padua), Valerio Pellegrini(University of Padua), Silvio Guerriero
Cited by 0
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709